Plain-English translation of NCT04721873 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a weight loss medication, can help people with ulcerative colitis who are also living with obesity. The study focuses on patients starting or continuing a biologic therapy (a special type of anti-inflammatory medicine). Researchers believe that losing weight while on biologic treatment might help control ulcerative colitis symptoms better and reduce inflammation more effectively.
About 20–40% of people with ulcerative colitis also have obesity, and research shows that extra weight makes the disease harder to control and increases the risk of flares, surgery, and treatment failure. While weight loss has helped people with other inflammatory conditions, there hasn't been much research on whether it helps ulcerative colitis specifically—this study aims to fill that gap.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the weight loss medication or a placebo (a pill with no active ingredient) for 22 weeks while you start or continue your biologic treatment for ulcerative colitis. During the study, you'll have regular visits with the research team to check your weight, symptoms, blood work, and biologic medication levels in your blood. The study will monitor whether the medication helps you lose weight, feel better, and respond more fully to your ulcerative colitis treatment.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States